Form 4: Regeneron's CEO Leonard S. Schleifer Executes Stock Option and Sells Shares Under 10b5-1 Plan

Regeneron's CEO, Leonard S. Schleifer, exercised stock options and sold shares between May 13 and May 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Leonard S. Schleifer, the Bd. Co-Chair, President & CEO of Regeneron Pharmaceuticals, Inc., executed a transaction involving the company's stock.
• On May 13, 2024, Schleifer exercised a non-qualified stock option to acquire 203,204 shares at a price of $399.66 per share.
• Also on May 13, 2024, 144,433 shares were disposed of to cover tax obligations at a price of $976.79.
• Between May 14 and May 15, 2024, Schleifer sold a total of 35,238 shares of common stock at prices ranging from $979.05 to $988.76.
• These transactions were executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 5, 2024.
• Following these transactions, Schleifer directly owns 397,259 shares of Regeneron common stock.
• Schleifer also indirectly owns 250,000 shares through a 2023 GRAT, 5,932 shares through a 401(k) plan, and 64,985 shares through a trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock and future prospects. The use of a 10b5-1 plan suggests that these transactions were pre-planned and not based on any specific non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as incentives, and subsequent sales are a normal part of wealth management.
• The use of a 10b5-1 trading plan is a common practice among corporate executives to avoid accusations of insider trading.
• Comparing Schleifer's transactions to those of executives at similar pharmaceutical companies (e.g., Amgen, Gilead, Pfizer) would provide context on the scale and frequency of such activities.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates